English
Back
Open Account
港股窩輪Jenny
commented on a stock · Mar 10 11:20

Wuxi Bio (02269) Short-term Analysis: RSI 35 approaching oversold, rebound target at $38.5 resistance

Entering mid-March, the Hong Kong stock pharmaceutical sector came under pressure. As of the morning session on March 10, 2026, Wuxi Bio's (02269) share price rebounded with the broader market, reaching a high of $36.68, and is currently trading at $35.94, up approximately 1.47%.
Looking at the performance of the same sector, pharmaceutical stocks generally recovered today. Wuxi Apptec (02359) is currently trading at $111, up 2.02%; Tigermed (03347) performed strongly, trading at $43.38, up 2.65%; and Chemtronics (03759) is at $19.01, up 1.22%. Overall, the CXO sector is showing signs of a rebound, with Wuxi Bio following the sector's recovery, albeit with slightly weaker gains compared to peers.
From a technical analysis perspective, Wuxi Bio’s share price (currently at $36.30) is constrained by the 10-day moving average ($37.88) and the 30-day moving average ($38.49), indicating clear short-term resistance. The Relative Strength Index (RSI) is at 35, nearing the oversold zone, with downward momentum weakening and technical rebound demand accumulating. The bull-bear power indicator has issued a buy signal, reflecting support at lower levels. The overall indicator signal is “Buy,” with a strength of 9, increasing expectations for a short-term rebound. Additionally, some technical analysts note that Wuxi Bio previously exhibited a "range breakout" pattern, falling below the bottom of the sideways range and trending softer, but the current level already shows potential for technical recovery.
In terms of support and resistance levels, the primary support is currently at $33.1, an important short-term line of defense; if it breaks, the next key support area would be $30.3. Resistance above is concentrated around $38.5 and $40.8, with $38.5 near the 10-day moving average being the first target for a short-term rebound. Considering the latest share price of $36.30, which is between the support at $33.1 and resistance at $38.5, short-term operations should consider range-bound fluctuations, waiting for opportunities to accumulate at lower prices or for a breakout signal.
Entering mid-March, the Hong Kong stock pharmaceutical sector came under pressure. As of the morning session on March 10, 2026, Wuxi Bio's (02269) share price rebounded with the broader market, reaching a high of $36.68, and is currently trading at $35.94, up approximately 1.47%. Looking at the performance of the same sector, pharmaceutical stocks generally recovered today. Wuxi Apptec (02359) is currently trading at $111, up 2.02%; Tigermed (03347) performed strongly, trading at $43.38, up 2.65%; and Chemtronics (03759) is at $19.01, up 1.22%. Overall, the CXO sector is showing signs of a rebound, with Wuxi Bio following the sector's recovery, albeit with slightly weaker gains compared to peers. From a technical analysis perspective, Wuxi Bio’s share price (currently at $36.30) is constrained by the 10-day moving average ($37.88) and the 30-day moving average ($38.49), indicating clear short-term resistance. The Relative Strength Index (RSI) is at 35, nearing the oversold zone, with downward momentum weakening and technical rebound demand accumulating. The bull-bear power indicator has issued a buy signal, reflecting support at lower levels. The overall indicator signal is “Buy,” with a strength of 9, increasing expectations for a short-term rebound. Additionally, some technical analysts note that Wuxi Bio previously exhibited a "range breakout" pattern, falling below the bottom of the sideways range and trending softer, but the current level already shows potential for technical recovery. In terms of support and resistance levels, the primary support is currently at $33.1, an important short-term line of defense; if it breaks, the next key support area will be...
Reviewing the performance of warrant products, the two Wuxi Bio bull contracts we mentioned on March 4 showed strong performance over the following two days, effectively capturing the rebound of the underlying stock. Societe Generale Bull (56391) $SG#WUXI RC2608B.C (56391.HK)$ recorded a 6% increase two days after being mentioned, while the underlying stock rose by 2.95% during the same period; UBS Group Bull (59459) $UB#WUXI RC2708D.C (59459.HK)$ surged by 11%. Both outperformed the underlying stock, demonstrating the leverage effect of bull contracts, with the UBS Group Bull showing particularly strong performance, reflecting higher sensitivity to fluctuations in the underlying stock due to its closer recovery price.
Entering mid-March, the Hong Kong stock pharmaceutical sector came under pressure. As of the morning session on March 10, 2026, Wuxi Bio's (02269) share price rebounded with the broader market, reaching a high of $36.68, and is currently trading at $35.94, up approximately 1.47%. Looking at the performance of the same sector, pharmaceutical stocks generally recovered today. Wuxi Apptec (02359) is currently trading at $111, up 2.02%; Tigermed (03347) performed strongly, trading at $43.38, up 2.65%; and Chemtronics (03759) is at $19.01, up 1.22%. Overall, the CXO sector is showing signs of a rebound, with Wuxi Bio following the sector's recovery, albeit with slightly weaker gains compared to peers. From a technical analysis perspective, Wuxi Bio’s share price (currently at $36.30) is constrained by the 10-day moving average ($37.88) and the 30-day moving average ($38.49), indicating clear short-term resistance. The Relative Strength Index (RSI) is at 35, nearing the oversold zone, with downward momentum weakening and technical rebound demand accumulating. The bull-bear power indicator has issued a buy signal, reflecting support at lower levels. The overall indicator signal is “Buy,” with a strength of 9, increasing expectations for a short-term rebound. Additionally, some technical analysts note that Wuxi Bio previously exhibited a "range breakout" pattern, falling below the bottom of the sideways range and trending softer, but the current level already shows potential for technical recovery. In terms of support and resistance levels, the primary support is currently at $33.1, an important short-term line of defense; if it breaks, the next key support area will be...
In terms of deploying warrant and bull-bear certificate products, investors can choose from the following products based on their own risk preferences, in conjunction with the current support and resistance levels.
In terms of call warrants, Bank of China Call Warrant (22714) $BI-WUXI@EC2611A.C (22714.HK)$ and Societe Generale Call Warrant (22583) $SG-WUXI@EC2611A.C (22583.HK)$ both have an exercise price of HKD 38.9, offering approximately 3.1 to 3.2 times leverage. This exercise price is linked to the key resistance levels between HKD 38.5 and HKD 40.8, making it suitable for investors expecting the stock price to break through resistance and recover upwards. The advantage of Bank of China Call Warrant (22714) lies in its relatively lower premium, keeping time value costs manageable; whereas Societe Generale Call Warrant (22583) offers more ideal leverage and implied volatility, making it more attractive for investors seeking amplified effects.
For bull contracts, Societe Generale Bull (66999) $SG#WUXI RC2606I.C (66999.HK)$ and UBS Group Bull (59460) $UB#WUXI RC2708E.C (59460.HK)$ both have a recovery price of HKD 29, providing around 4.1 to 4.4 times actual leverage. This recovery price is below the primary support level of HKD 33.1, offering ample buffer space, and is suitable for investors expecting the stock price to stabilize at the HKD 33.1 support level and rebound. The advantage of Societe Generale Bull (66999) lies in its lowest premium and highest actual leverage at 4.4 times; whereas UBS Group Bull (59460) provides the highest actual leverage at 4.1 times, making it equally appealing for investors seeking amplified effects.
Entering mid-March, the Hong Kong stock pharmaceutical sector came under pressure. As of the morning session on March 10, 2026, Wuxi Bio's (02269) share price rebounded with the broader market, reaching a high of $36.68, and is currently trading at $35.94, up approximately 1.47%. Looking at the performance of the same sector, pharmaceutical stocks generally recovered today. Wuxi Apptec (02359) is currently trading at $111, up 2.02%; Tigermed (03347) performed strongly, trading at $43.38, up 2.65%; and Chemtronics (03759) is at $19.01, up 1.22%. Overall, the CXO sector is showing signs of a rebound, with Wuxi Bio following the sector's recovery, albeit with slightly weaker gains compared to peers. From a technical analysis perspective, Wuxi Bio’s share price (currently at $36.30) is constrained by the 10-day moving average ($37.88) and the 30-day moving average ($38.49), indicating clear short-term resistance. The Relative Strength Index (RSI) is at 35, nearing the oversold zone, with downward momentum weakening and technical rebound demand accumulating. The bull-bear power indicator has issued a buy signal, reflecting support at lower levels. The overall indicator signal is “Buy,” with a strength of 9, increasing expectations for a short-term rebound. Additionally, some technical analysts note that Wuxi Bio previously exhibited a "range breakout" pattern, falling below the bottom of the sideways range and trending softer, but the current level already shows potential for technical recovery. In terms of support and resistance levels, the primary support is currently at $33.1, an important short-term line of defense; if it breaks, the next key support area will be...
Entering mid-March, the Hong Kong stock pharmaceutical sector came under pressure. As of the morning session on March 10, 2026, Wuxi Bio's (02269) share price rebounded with the broader market, reaching a high of $36.68, and is currently trading at $35.94, up approximately 1.47%. Looking at the performance of the same sector, pharmaceutical stocks generally recovered today. Wuxi Apptec (02359) is currently trading at $111, up 2.02%; Tigermed (03347) performed strongly, trading at $43.38, up 2.65%; and Chemtronics (03759) is at $19.01, up 1.22%. Overall, the CXO sector is showing signs of a rebound, with Wuxi Bio following the sector's recovery, albeit with slightly weaker gains compared to peers. From a technical analysis perspective, Wuxi Bio’s share price (currently at $36.30) is constrained by the 10-day moving average ($37.88) and the 30-day moving average ($38.49), indicating clear short-term resistance. The Relative Strength Index (RSI) is at 35, nearing the oversold zone, with downward momentum weakening and technical rebound demand accumulating. The bull-bear power indicator has issued a buy signal, reflecting support at lower levels. The overall indicator signal is “Buy,” with a strength of 9, increasing expectations for a short-term rebound. Additionally, some technical analysts note that Wuxi Bio previously exhibited a "range breakout" pattern, falling below the bottom of the sideways range and trending softer, but the current level already shows potential for technical recovery. In terms of support and resistance levels, the primary support is currently at $33.1, an important short-term line of defense; if it breaks, the next key support area will be...
Regarding bear contracts, J.P. Morgan Bear (61915) has a recovery price of HKD 45, with a distance to recovery ratio of about 20.13%, offering 3.82 times actual leverage. This recovery price is linked above the key resistance level of HKD 40.8, making it suitable for investors expecting the stock price rebound to be capped by resistance. Another J.P. Morgan Bear (59474) has a recovery price of HKD 47.7, with a distance to recovery ratio of about 24.61%, offering 3.05 times actual leverage and a premium of 4%, providing broader defensive space, suitable for investors sensitive to recovery risks.
Entering mid-March, the Hong Kong stock pharmaceutical sector came under pressure. As of the morning session on March 10, 2026, Wuxi Bio's (02269) share price rebounded with the broader market, reaching a high of $36.68, and is currently trading at $35.94, up approximately 1.47%. Looking at the performance of the same sector, pharmaceutical stocks generally recovered today. Wuxi Apptec (02359) is currently trading at $111, up 2.02%; Tigermed (03347) performed strongly, trading at $43.38, up 2.65%; and Chemtronics (03759) is at $19.01, up 1.22%. Overall, the CXO sector is showing signs of a rebound, with Wuxi Bio following the sector's recovery, albeit with slightly weaker gains compared to peers. From a technical analysis perspective, Wuxi Bio’s share price (currently at $36.30) is constrained by the 10-day moving average ($37.88) and the 30-day moving average ($38.49), indicating clear short-term resistance. The Relative Strength Index (RSI) is at 35, nearing the oversold zone, with downward momentum weakening and technical rebound demand accumulating. The bull-bear power indicator has issued a buy signal, reflecting support at lower levels. The overall indicator signal is “Buy,” with a strength of 9, increasing expectations for a short-term rebound. Additionally, some technical analysts note that Wuxi Bio previously exhibited a "range breakout" pattern, falling below the bottom of the sideways range and trending softer, but the current level already shows potential for technical recovery. In terms of support and resistance levels, the primary support is currently at $33.1, an important short-term line of defense; if it breaks, the next key support area will be...
Overall, investors who are optimistic about Wuxi Bio's rebound can pay attention to Societe Generale call warrants (22583) to capture a breakout rally, or Societe Generale bull contracts (66999) for higher leverage; bearish investors may consider J.P. Morgan bear contracts (61915) to capture the downturn with higher leverage, or J.P. Morgan bear contracts (59474) with larger buffer zones to reduce forced recovery risks.
Interactive Questions:
Dear readers, Wuxi Bio (02269) currently has an RSI of 35, approaching the oversold zone. Do you think it will successfully rebound in the short term and retest 38.5 yuan?
A) Yes, there is strong technical rebound demand, and it is expected to recover the 10-day moving average.
B) No, consolidation near 33.1 yuan is needed first, and clear sector direction is required before a strong upward move.
Feel free to share your thoughts in the comments section!
Reminder: This article does not constitute any investment advice.
This article is for reference only and does not constitute any investment advice. The market data, opinions, and analysis contained herein may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only shows whether certain technical conditions are met; a comprehensive assessment of asset performance should combine other data and should not solely rely on this article to make trading decisions. Please note that past performance is not indicative of future results. Follow Jenny's insights on Hong Kong stock warrants for more professional analysis.
#WuXi Biologics #02269 #Hong Kong Stocks #Technical Analysis #Support and Resistance Levels #Warrants #Bull and Bear Certificates #Call Options #Put Options #Pharmaceutical Sector
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
2
195K Views
Report
Comments
Write a Comment...
2
1